^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iCasp9M28z T cell infusion

    i
    Other names: iCasp9M28z T cell infusion, genetically engineered anti-mesothelin autologous T cells
    Associations

    News

    Trials
    Company:
    Bellicum, Memorial Sloan-Kettering Cancer Center
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    7ms
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • iCasp9M28z T cell infusion
    over2years
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • iCasp9M28z T cell infusion
    3years
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=179 --> 113
    Clinical • Enrollment closed • Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • iCasp9M28z T cell infusion
    over3years
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=179, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2021 --> Apr 2023 | Trial primary completion date: Apr 2021 --> Apr 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide intravenous • iCasp9M28z T cell infusion
    over4years
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=179, Recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P1 --> P1/2 | N=66 --> 179
    Clinical • Phase classification • Enrollment change • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide intravenous • iCasp9M28z T cell infusion
    almost5years
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1, N=66, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
    Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide intravenous • iCasp9M28z T cell infusion